172 related articles for article (PubMed ID: 38541177)
1. Effective Differences between 2D and 3D Planned Brachytherapy in Lung Cancer: An Institutional Retrospective Study.
Lalić N; Bojović M; Ivanov O; Ličina J; Popević S; Stjepanović M; Bursać D; Lalić I; Milić R; Tomić S; Parapid B; Anđelković A
Medicina (Kaunas); 2024 Mar; 60(3):. PubMed ID: 38541177
[No Abstract] [Full Text] [Related]
2. Endobronchial brachytherapy for symptom palliation in non-small cell lung cancer--analysis of symptom response, endoscopic improvement and quality of life.
Mallick I; Sharma SC; Behera D
Lung Cancer; 2007 Mar; 55(3):313-8. PubMed ID: 17157949
[TBL] [Abstract][Full Text] [Related]
3. Optimization of dose and fractionation of endobronchial brachytherapy with or without external radiation in the palliative management of non-small cell lung cancer: a prospective randomized study.
Mallick I; Sharma SC; Behera D; Ghoshal S; Oinam AS
J Cancer Res Ther; 2006; 2(3):119-25. PubMed ID: 17998689
[TBL] [Abstract][Full Text] [Related]
4. High-dose-rate endobronchial brachytherapy effectively palliates symptoms due to airway tumors: the 10-year M. D. Anderson cancer center experience.
Kelly JF; Delclos ME; Morice RC; Huaringa A; Allen PK; Komaki R
Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):697-702. PubMed ID: 11020566
[TBL] [Abstract][Full Text] [Related]
5. A prospective analysis of high-dose-rate endobronchial brachytherapy in the palliation of obstructive symptoms in lung cancer patients: A single-institution experience.
Goldberg M; Timotin E; Farrell T; Puksa S; Donde B; Sur R
Brachytherapy; 2015; 14(5):655-61. PubMed ID: 25983031
[TBL] [Abstract][Full Text] [Related]
6. [Endoluminal HDR brachytherapy in the palliative treatment of patients with the recurrence of a non-small-cell bronchial carcinoma after prior radiotherapy].
Micke O; Prott FJ; Schäfer U; Wagner W; Pötter R; Willich N
Strahlenther Onkol; 1995 Oct; 171(10):554-9. PubMed ID: 8571174
[TBL] [Abstract][Full Text] [Related]
7. High dose rate endobronchial brachytherapy effectively palliates symptoms due to inoperable lung cancer.
Celebioglu B; Gurkan OU; Erdogan S; Savas I; Köse K; Kurtman C; Gonullu U
Jpn J Clin Oncol; 2002 Nov; 32(11):443-8. PubMed ID: 12499415
[TBL] [Abstract][Full Text] [Related]
8. Clinical risk factors for early complications after high-dose-rate endobronchial brachytherapy in the palliative treatment of lung cancer.
Zaric B; Perin B; Jovelic A; Lalic N; Secen N; Kopitovic I; Antonic M
Clin Lung Cancer; 2010 May; 11(3):182-6. PubMed ID: 20439194
[TBL] [Abstract][Full Text] [Related]
9. The use of high dose rate endobronchial brachytherapy to palliate symptomatic recurrence of previously irriadiated lung cancer.
Kubaszewska M; Skowronek J; Chicheł A; Kanikowski M
Neoplasma; 2008; 55(3):239-45. PubMed ID: 18348661
[TBL] [Abstract][Full Text] [Related]
10. [The role of high dose rate (HDR) brachytherapy in advanced non-small cell lung cancer].
Makarewicz R
Pneumonol Alergol Pol; 2002; 70(5-6):265-77. PubMed ID: 12518625
[TBL] [Abstract][Full Text] [Related]
11. [Brachytherapy in the treatment of lung and tracheal cancer: current indications, methods, results].
Skowronek J; Młynarczyk W; Piorunek T
Przegl Lek; 2006; 63(8):664-73. PubMed ID: 17441380
[TBL] [Abstract][Full Text] [Related]
12. 3D-image-guided HDR-brachytherapy versus 2D HDR - brachytherapy after external beam radiotherapy for early T-stage nasopharyngeal carcinoma.
Ren Y; Zhao Q; Liu H; Huang Y; Wang Z; Cao X; Teh BS; Wen B
BMC Cancer; 2014 Nov; 14():894. PubMed ID: 25432818
[TBL] [Abstract][Full Text] [Related]
13. High dose rate afterloading intraluminal brachytherapy in malignant airway obstruction of lung cancer.
Chang LF; Horvath J; Peyton W; Ling SS
Int J Radiat Oncol Biol Phys; 1994 Feb; 28(3):589-96. PubMed ID: 7509330
[TBL] [Abstract][Full Text] [Related]
14. [High-dose endobronchial brachytherapy in malignant tumors of the lung].
Escobar Sacristán J; de Granda Orive JI; Gutiérrez Jiménez T; Martínez Albiach JM; Fuentes Ramos M; Herrera de la Rosa A
Arch Bronconeumol; 1997 Jun; 33(6):278-83. PubMed ID: 9289322
[TBL] [Abstract][Full Text] [Related]
15. Palliative high-dose-rate endobronchial brachytherapy for recurrent carcinoma: the University of Louisville experience.
Guarnaschelli JN; Jose BO
J Palliat Med; 2010 Aug; 13(8):981-9. PubMed ID: 20666622
[TBL] [Abstract][Full Text] [Related]
16. External irradiation versus external irradiation plus endobronchial brachytherapy in inoperable non-small cell lung cancer: a prospective randomized study.
Langendijk H; de Jong J; Tjwa M; Muller M; ten Velde G; Aaronson N; Lamers R; Slotman B; Wouters M
Radiother Oncol; 2001 Mar; 58(3):257-68. PubMed ID: 11230886
[TBL] [Abstract][Full Text] [Related]
17. Effect and toxicity of endoluminal high-dose-rate (HDR) brachytherapy in centrally located tumors of the upper respiratory tract.
Harms W; Schraube P; Becker H; Latz D; Herth F; Fritz P; Wannenmacher M
Strahlenther Onkol; 2000 Feb; 176(2):60-6. PubMed ID: 10697652
[TBL] [Abstract][Full Text] [Related]
18. High dose rate intraluminal brachytherapy in the treatment of malignant airway obstructions.
Petera J; Spásová I; Neumanová R; Skricková J; Salajka F; Hrazdírová A; Kaplanová J; Coupková H; Coupek P; Kucera M
Neoplasma; 2001; 48(2):148-53. PubMed ID: 11478697
[TBL] [Abstract][Full Text] [Related]
19. High-dose-rate brachytherapy in combination with stenting offers a rapid and statistically significant improvement in quality of life for patients with endobronchial recurrence.
Allison R; Sibata C; Sarma K; Childs CJ; Downie GH
Cancer J; 2004; 10(6):368-73. PubMed ID: 15701268
[TBL] [Abstract][Full Text] [Related]
20. Local determinants of response to endobronchial high-dose rate brachytherapy in bronchogenic carcinoma.
Ofiara L; Roman T; Schwartzman K; Levy RD
Chest; 1997 Oct; 112(4):946-53. PubMed ID: 9377957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
